SARS-CoV-2 is currently causing a devastating pandemic and there is a pressing need to understand the dynamics, specificity, and neutralizing potency of the humoral immune response during acute infection. Herein, we report the dynamics of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in 44 COVID-19 patients. RBD-specific IgG responses were detectable in all patients 6 days after PCR confirmation. Using a clinical isolate of SARS-CoV-2, neutralizing antibody titers were also detectable in all patients 6 days after PCR confirmation. The magnitude of RBD-specific IgG binding titers correlated strongly with viral neutralization. In a clinical setting, the initial analysis of the dynamics of RBD-specific IgG titers was corroborated in a larger cohort of PCR-confirmed patients (n=231). These findings have important implications for our understanding of protective immunity against SARS-CoV-2, the use of immune plasma as a therapy, and the development of much-needed vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274246 | PMC |
| http://dx.doi.org/10.1101/2020.05.03.20084442 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles.
Vaccine
December 2024
Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia. Electronic address:
Recombinant influenza viruses are promising vectors that can bolster antibody and resident lymphocyte responses within mucosal sites. This study evaluates recombinant influenza viruses with SARS-CoV-2 RBD genes in eliciting mucosal and systemic responses. Using reverse genetics, we generated replication-competent recombinant influenza viruses carrying heterologous RBD genes in monomeric, trimeric, or ferritin-based nanoparticle forms.
View Article and Find Full Text PDFRapid Sterilization of Clinical Apheresis Blood Products using Ultra-High Dose Rate Radiation.
bioRxiv
December 2024
Stanford Blood Center, Stanford Health Care, Stanford, California, USA.
Background And Objectives: Apheresis platelets products and plasma are essential for medical interventions, but both still have inherent risks associated with contamination and viral transmission. Platelet products are vulnerable to bacterial contamination due to storage conditions, while plasma requires extensive screening to minimize virus transmission risks. Here we investigate rapid irradiation to sterilizing doses for bacteria and viruses as an innovative pathogen reduction technology.
View Article and Find Full Text PDFProthrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19.
Blood
November 2024
Versiti / Blood Research Institute, Milwaukee, Wisconsin, United States.
Thromboembolic complication is common in severe coronavirus disease (COVID-19), leading to an investigation into the presence of prothrombotic antibodies akin to those found in heparin-induced thrombocytopenia (HIT). In a study of samples from 130 hospitalized patients collected 3.6 days after COVID-19 diagnosis, 80% had IgG antibodies recognizing complexes of heparin and platelet factor 4 (PF4/H), and 41% had antibodies inducing PF4-dependent P-selectin expression in CpG-treated normal platelets.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines how exposure to wildfire smoke impacts immune responses in individuals receiving the Pfizer COVID-19 vaccine, focusing on the role of Natural Killer (NK) cells.
- - Researchers analyzed blood samples from 52 participants before and after vaccine administration during heavy wildfire smoke events, finding variations in IgG antibody levels associated with air quality.
- - Results indicate that wildfire smoke exposure may disrupt immune function by affecting NK cell activity, leading to reduced vaccine efficacy over time.
Absolute concentration estimation of COVID-19 convalescent and post-vaccination IgG antibodies.
PLoS One
November 2024
Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States of America.
Article Synopsis
- - The study investigates antibody concentrations and binding affinities in convalescent plasma and post-vaccination samples from COVID-19 patients, focusing on the spike protein of the virus, which is crucial for protective immunity.
- - Using enzyme-linked immunosorbent assays (ELISAs), researchers measured IgG antibodies and found a protective antibody level of 7.5 μg/ml in post-vaccination samples, with similar concentrations in both convalescent and post-vaccination groups.
- - The results indicate that individuals who received only one dose of the BNT162b2 or mRNA-1273 vaccines had significantly lower antibody concentrations, highlighting the importance of full vaccination for effective immunity and informing future vaccine
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!